VEGFA and neoplasm: Bevacizumab, a monoclonal antibody directed against VEGF, has been approved for the treatment of several solid tumors inducing a re-modulation of tumor vessels, increasing B and T cell recruitment, and improving immune response (Roviello et al., 2017).